SG11202006990TA - Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent - Google Patents
Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agentInfo
- Publication number
- SG11202006990TA SG11202006990TA SG11202006990TA SG11202006990TA SG11202006990TA SG 11202006990T A SG11202006990T A SG 11202006990TA SG 11202006990T A SG11202006990T A SG 11202006990TA SG 11202006990T A SG11202006990T A SG 11202006990TA SG 11202006990T A SG11202006990T A SG 11202006990TA
- Authority
- SG
- Singapore
- Prior art keywords
- plinabulin
- administration
- composition
- induced neutropenia
- reducing chemotherapy
- Prior art date
Links
- 238000002512 chemotherapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 208000004235 neutropenia Diseases 0.000 title 1
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 title 1
- 229950011498 plinabulin Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862625290P | 2018-02-01 | 2018-02-01 | |
US201862713486P | 2018-08-01 | 2018-08-01 | |
US201862749060P | 2018-10-22 | 2018-10-22 | |
US201862757648P | 2018-11-08 | 2018-11-08 | |
PCT/US2019/015867 WO2019152530A1 (en) | 2018-02-01 | 2019-01-30 | Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202006990TA true SG11202006990TA (en) | 2020-08-28 |
Family
ID=67479904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202006990TA SG11202006990TA (en) | 2018-02-01 | 2019-01-30 | Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210030843A1 (ko) |
EP (1) | EP3746076A4 (ko) |
JP (2) | JP2021512121A (ko) |
KR (1) | KR20200116477A (ko) |
CN (1) | CN112105363A (ko) |
AU (1) | AU2019216305A1 (ko) |
BR (1) | BR112020015758A2 (ko) |
CA (1) | CA3089391A1 (ko) |
IL (1) | IL276197A (ko) |
SG (1) | SG11202006990TA (ko) |
WO (1) | WO2019152530A1 (ko) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3265090A4 (en) | 2015-03-06 | 2018-08-01 | Beyondspring Pharmaceuticals Inc. | Method of treating cancer associated with a ras mutation |
EP3334726B1 (en) | 2015-07-13 | 2022-03-16 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
MY192703A (en) | 2016-02-08 | 2022-09-02 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
MX2018015100A (es) | 2016-06-06 | 2019-09-04 | Beyondspring Pharmaceuticals Inc | Composicion y metodo para reducir la neutropenia. |
JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
WO2018144764A1 (en) | 2017-02-01 | 2018-08-09 | Beyondspring Pharmaceuticals, Inc. | Method of reducing neutropenia |
KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
US11684655B2 (en) | 2019-05-31 | 2023-06-27 | Spectrum Pharmaceuticals, Inc. | Methods of treating neutorpenia using G-CSF protein complex |
JP2022552011A (ja) * | 2019-10-15 | 2022-12-14 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | 鉄障害を処置するための方法及び組成物 |
JP2023505506A (ja) * | 2019-12-05 | 2023-02-09 | ハンミ ファーマシューティカルズ カンパニー リミテッド | 化学療法または放射線療法で誘導された好中球減少症を治療する方法 |
CA3186416A1 (en) * | 2020-07-17 | 2022-01-20 | John A. Barrett | Methods of treating chemotherapy induced neutropenia using fixed doses of g-csf protein complex |
WO2022133492A1 (en) * | 2020-12-18 | 2022-06-23 | Beyondspring Pharmaceuticals, Inc. | Compositions and methods for generating anti-tumor immune response |
KR102375269B1 (ko) * | 2021-01-27 | 2022-03-17 | 한미약품 주식회사 | 단백질 액상 제제 및 이의 제조방법 |
CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012515222A (ja) * | 2009-01-16 | 2012-07-05 | テバ ファーマシューティカル インダストリーズ リミテッド | 組換えヒトアルブミン−ヒト顆粒球コロニー刺激因子融合タンパク質の安定な製剤 |
MX2016004441A (es) * | 2013-10-11 | 2016-10-28 | Beyondspring Inc | Tratamiento del cancer con una combinacion de plinabulina y taxano. |
MX2018015100A (es) * | 2016-06-06 | 2019-09-04 | Beyondspring Pharmaceuticals Inc | Composicion y metodo para reducir la neutropenia. |
WO2018144764A1 (en) * | 2017-02-01 | 2018-08-09 | Beyondspring Pharmaceuticals, Inc. | Method of reducing neutropenia |
-
2019
- 2019-01-30 EP EP19746727.7A patent/EP3746076A4/en active Pending
- 2019-01-30 US US16/966,156 patent/US20210030843A1/en active Pending
- 2019-01-30 JP JP2020541924A patent/JP2021512121A/ja active Pending
- 2019-01-30 CN CN201980018772.9A patent/CN112105363A/zh active Pending
- 2019-01-30 AU AU2019216305A patent/AU2019216305A1/en active Pending
- 2019-01-30 KR KR1020207024515A patent/KR20200116477A/ko active Search and Examination
- 2019-01-30 SG SG11202006990TA patent/SG11202006990TA/en unknown
- 2019-01-30 WO PCT/US2019/015867 patent/WO2019152530A1/en unknown
- 2019-01-30 CA CA3089391A patent/CA3089391A1/en active Pending
- 2019-01-30 BR BR112020015758-9A patent/BR112020015758A2/pt unknown
-
2020
- 2020-07-21 IL IL276197A patent/IL276197A/en unknown
-
2023
- 2023-11-30 JP JP2023202765A patent/JP2024015120A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2019216305A1 (en) | 2020-08-27 |
WO2019152530A1 (en) | 2019-08-08 |
KR20200116477A (ko) | 2020-10-12 |
US20210030843A1 (en) | 2021-02-04 |
JP2021512121A (ja) | 2021-05-13 |
BR112020015758A2 (pt) | 2020-12-08 |
NZ766454A (en) | 2024-02-23 |
EP3746076A1 (en) | 2020-12-09 |
RU2020126600A (ru) | 2022-03-01 |
CA3089391A1 (en) | 2019-08-08 |
CN112105363A (zh) | 2020-12-18 |
EP3746076A4 (en) | 2021-12-22 |
JP2024015120A (ja) | 2024-02-01 |
IL276197A (en) | 2020-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276197A (en) | Composition and method for reducing the neutrophil deficiency caused by chemotherapy through the administration of palinabolin and G-CSF factor | |
IL283840A (en) | Preparations for administering therapeutic substances and methods for their use and preparation | |
IL283177A (en) | Preparations and methods for delivering a specific charge to a cell | |
EP3813853A4 (en) | DELIVERY COMPOSITIONS AND METHODS OF USE | |
IL276148A (en) | A preparation and method for reducing platelet count through the administration of palinabolin | |
EP3946547A4 (en) | DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS | |
EP3838265A4 (en) | INJECTABLE PHARMACEUTICAL COMPOSITION AND METHOD FOR PREPARATION | |
EP4074334A4 (en) | PHARMACEUTICAL COMPOSITION AND ITS USE | |
EP3773654C0 (en) | POLYPHARMACEUTICAL DRUG COMPOSITIONS AND ASSOCIATED METHODS | |
EP3760191A4 (en) | PHARMACEUTICAL COMPOSITION, PROCESS FOR PREPARATION AND USE OF THE LATTER | |
EP4048230C0 (en) | ORAL GLIPTIN COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF | |
EP3982942A4 (en) | DRUG DELIVERY METHODS AND COMPOSITIONS | |
IL287137A (en) | Preparations and methods for administration of healing substances | |
EP3485876A4 (en) | ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING A PARTICULATE FORMULATION WITH THE COMPOSITION | |
EP3813842A4 (en) | PHARMACEUTICAL COMPOSITION AND MANUFACTURING PROCESS THEREOF | |
EP3824888A4 (en) | ORAL PHARMACEUTICAL COMPOSITION WITH FAB-I INHIBITORS AND PROCESS FOR THEIR MANUFACTURE | |
IL284132A (en) | A pharmaceutical compound, a method for its preparation and its use as a medicinal substance | |
ZA202104261B (en) | Combination pharmaceutical compositions and methods thereof | |
IL281080A (en) | Preparations containing a compound containing selenite and a pharmaceutically acceptable acid for the treatment of human papillomavirus infection | |
IL281073A (en) | History of imidazopyridine and pharmaceutical preparations containing them | |
EP3781194A4 (en) | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | |
SG11202101547WA (en) | Pharmaceutical composition for oral administration | |
EP3804722A4 (en) | TREATMENT AGENT AND PHARMACEUTICAL COMPOSITION AGAINST GLIOMA | |
EP3790543A4 (en) | COMPOSITIONS AND DOSAGE FORMS FOR ORAL ADMINISTRATION | |
EP3773732A4 (en) | METHODS AND COMPOSITIONS FOR THE ADMINISTRATION OF A THERAPEUTIC AGENT |